Patent infringement plaintiffs rejoice: Appeals court raises the bar for inequitable conduct | Legal News

Becton, Dickinson

A federal appeals court made it harder for defendants in patent infringement cases to use an "atomic bomb" defense tactic called inequitable conduct in a lawsuit between an Abbott (NYSE:ABT) subsidiary and Becton, Dickinson & Co. (NYSE:BDX).

The inequitable conduct defense, which one study estimated is used in 80 percent of patent infringement cases, is an accusation that, but for evidence concealed by a patent applicant, the U.S. Patent & Trademark Office would not have approved a patent. If a judge agrees, the defense gambit invalidates the patent and can even threaten the validity of entire patent portfolios.

In Therasense, Inc. v. Becton, Dickinson and Co., Nova Biomedical Corp. and Bayer Healthcare LLC, The U.S. Court of Appeals for the Federal Circuit tightened the standards by which inequitable conduct can be found. The case involves the intellectual property behind blood glucose test strips; Abbott subsidiary Therasense sued BD and the other defendants in a series of suits that were consolidated in the U.S. District Court for Northern California.

That court found one of the Abbott patents unenforceable due to inequitable conduct; Abbott appealed to the Federal Circuit, which upheld the lower court’s ruling. But Abbott asked that court for an en banc review of the case, which vacated its earlier judgment and the lower court decision last week.

BD moved to stay the judgment pending its appeal to have the U.S. Supreme Court hear the case. If the high court refuses to hear the case, as some legal eagles expect, it will have far-reaching consequences for patent infringement litigation.

Before Therasense, a sliding scale was used to prove inequitable conduct, according to David Dykeman, a shareholder and patent attorney at Greenberg Traurig LLP. The scale applied to whether the alleged conduct would have had a material effect on how the USPTO reviewed the patent in question — that is, whether a "reasonable examiner" would have rejected the patent if the hidden information had been available. A finding of inequitable conduct also depended on proving that the patent applicant intended to deceive the USPTO.

"The case raised the standard for proving inequitable conduct," Dykeman said "The inequitable conduct defense will be harder to prove, as the accuser must prove both intent and materiality by ‘clear and convincing’ evidence."

If Rader’s ruling stands, defendants alleging inequitable conduct will now have to prove that the patent holder deliberately pulled the wool over the patent reviewer’s eyes. Intent can still be inferred from indirect or circumstantial evidence, but only if it’s "the single most reasonable inference able to be drawn from the evidence." And, to prove materiality, defendants would have to meet a "but-for" standard — or demonstrate that, but for the hidden material, the patent office would have rejected the application.

Judge Randall Rader, chief of the Federal Circuit court, called the IC defense the "atomic bomb" of patent law:

"Unlike validity defenses, which are claim-specific, inequitable conduct regarding any single claim renders the entire patent unenforceable. Unlike other deficiencies, inequitable conduct cannot be cured by reissue or reexamination. Moreover, the taint of a finding of inequitable conduct can spread from a single patent to render unenforceable other related patents and applications in the same technology family. Thus, a finding of inequitable conduct may endanger a substantial portion of a company’s patent portfolio.

“While honesty at the PTO is essential, low standards for intent and materiality have inadvertently led to many unintended consequences, among them, increased adjudication cost and complexity, reduced likelihood of settlement, burdened courts, strained PTO resources, increased PTO backlog, and impaired patent quality. This court now tightens the standards for finding both intent and materiality in order to redirect a doctrine that has been overused to the detriment of the public."


Obama administration backs House patent reform bill

President Barack Obama’s administration is backing a bill in the U.S. House of Representatives that would change the way the USPTO is run — and give it the power to set its own fees.

Patent reform legislation has been bouncing around inside the Beltway for more than half a decade. The latest iteration would overturn centuries of patent practice, which recognized patents by the first inventors to file. The new system would allow reviewers to determine who was the first to produce the invention.

The bill would also create a one-year post-grant review window allowing for challenges to the patent.

That would "create a much easier and less-expensive vehicle to challenge an issued patent," Dykeman said.

A similar measure, with a nine-month challenge window and similar changes to the first-to-file system, passed the U.S. Senate in March.

American Medical Systems settles suits to let Endo merger go forward

American Medical Systems Holdings Inc. (NSDQ:AMMD) is looking to settle lawsuits filed to block its $2.9 billion merger with Endo Pharmaceuticals Holdings Inc. (NSDQ:ENDP).

The Minnetonka, Minn.-based urology device maker said it agreed to settle the suits "solely to avoid the costs, risks and uncertainties inherent in litigation, and without admitting any liability or wrongdoing."

AMMD also agreed to disclose additional information about the negotiations behind the merger and to pay the plaintiffs’ legal fees.
Read more

Histogen declares (premature?) victory in patent spat with SkinMedica

San Diego-based Histogen Inc. is touting a ruling by the U.S. District Court for Southern California in its patent spat with competitor SkinMedica Inc., which sued in 2009 over a pair of patents covering skin cell cultures.

"With this result, Histogen has prevailed on the key claim interpretation relevant to the lawsuit filed by SkinMedica," according to the press release. "This important ruling should lead to the trial court’s dismissal of the patent infringement allegations against Histogen."
Read more

RSS From Medical Design & Outsourcing

  • Albright Technologies expands their silicone offerings
    Albright Technologies, a rapid silicone prototyper, has added silicone injection molding tooling and services to its product lineup. Liquid silicone injection molding became a suitable product offering as Albright expanded its offerings to better serve the silicone molding market. While silicone prototypes are commonly manufactured with low volumes in mind; injection molded liquid silicone rubber parts are […]
  • Applied Silver launches SilvaClean, silver treatment for textiles
    Applied Silver, Inc, is launching SilvaClean, a state-of-the-art silver treatment for textiles, at the Association for Professionals in Infection Control and Epidemiology’s (APIC) forty-second Annual Conference taking place at the Music City Center in Nashville, from June 27 through June 29. Hospitals have invested significantly in reducing the potential of infection through products and processes designed […]
  • Two-Component technology for improved quality of life
    In the field of injection molding and mold making, toolcraft covers all processes within the added value chain–from the design and selection of materials through to the creation of finished and qualified products. Complete solutions offered include injection molding for parts in the small and extremely small component areas, e.g. for medical technology. Utilizing two-component […]
  • GDS security protects medical devices from hackers
    As data breaches become more commonplace with serious consequences to personal, corporate and national security, it is clear that there is no shortage of accomplished and effective hackers ready to steal data and trade it on the open market. Global Data Sentinel (GDS) has the ability to provide retroactive security to remove access to email […]
  • BRAEBON and SomnoMed combine products to combat sleep apnea
    BRAEBON Medical Corporation announces that the DentiTrac oral appliance compliance system has passed a regulatory hurdle and is now FDA cleared in the USA for use with the SomnoDent oral device. BRAEBON congratulates SomnoMed for being the first company to achieve this milestone. “We are pleased DentiTrac is launching in the US market. Accurate oral appliance […]
  • For advanced shielded plastic connector solution, ODU delivers with latest product
    ODU, a company which designs and manufactures connector solutions and cable assemblies, is announcing ODU MEDI-SNAP EMC, the advanced shielded plastic connector solutions, to the US market. ODU MEDI-SNAP EMC is the latest addition to ODU’s Push-Pull circular connectors. The advanced medical connector solution is lightweight, autoclavable, sterilizable and it offers a touch proofed housing and reliable […]
  • LifeVac steps towards availability on European markets
    On June 16, 2015, LifeVac Europe received confirmation from the UK Ministry of Health that LifeVac is now registered in the Medicines and Healthcare products Regulatory Agency public access data base. This is the final step towards acquiring the CE mark and making LifeVac available to the entire European market. “We are very excited to […]
  • A few ideas for improving productivity in medical processes
    Drive-based vibration and slosh control can help improve throughput in machines that assemble medical devices and products. Bipin Sen • Ed Lasch Bosch Rexroth Corporation Simply increasing the speed of a system that assembles medical devices, or packages medical products, seems like an easy way to boost throughput – until unwanted vibration (either induced […]
  • ODU announces MEDI-SNAP EMC for next generation medical applications
    ODU, announced ODU MEDI-SNAP EMC, the advanced shielded plastic connector solutions to the US market. ODU MEDI-SNAP EMC is the newest addition to ODU’s Push-Pull circular connectors. The advanced medical connector solution is lightweight, autoclavable, sterilizable and it offers a touch proofed housing and reliable EMI protection at the same time. ODU MEDI-SNAP EMC is available in […]
  • Evaluating the risk of device misconnections: Designing for medical devices with ISO 80369 in mind
    Beginning in the 1990s, concerns grew regarding the proliferation of medical devices fitted with luer connectors and the reports of patient injuries and deaths arising from misconnections. Thus began a many-years process to develop new industry standards for the small-bore connectors used in medical device applications. The much-anticipated ISO 80369 series of standards for small-bore […]
  • Custom molded filter screen assemblies limit contamination and reduce product failure
    Molded screen insert assemblies from Minnesota Rubber and Plastics are custom designed for water, beverage, off-highway and transportation applications to filter out fluid contaminants and reduce product failure. A wide range of screen options are available in many materials for difficult filtration applications allowing use with different fluids. Filter assembly orifice sizes available range from .71 […]

Leave a Reply